UPDATE: Wedbush Starts Y-mAbs Therapeutics Inc. (YMAB) at Outperform
- Wall Street extends rally as economically sensitive sectors bounce
- China Tells Local Authorities to Prepare For a 'Possible Storm' and Prevent Unrest as Evergrande Crisis Unravels - WSJ
- Salesforce (CRM) Raises FY22 Revenue Guidance; Initiates FY23 Revenue
- Oil prices at two-month highs on tight supplies
- IDFA Seen as a 'Real Headwind' for Facebook (FB) but Analysts Remain Positive
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
(Updated - September 3, 2019 4:16 PM EDT)
(updated to correct ticker)
Wedbush analyst David Nierengarten initiates coverage on Y-mAbs Therapeutics (NASDAQ: YMAB)) with a Outperform rating and a price target of $38.00.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Tudor Pickering Starts Tesla (TSLA) at Sell
- Wolfe Research Starts Brixmor Property (BRX) at Peerperform
- UPDATE: Cowen Starts Danimer Scientific (DNMR) at Outperform
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!